Drg Stimulator denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for drg stimulator are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied a Dorsal Root Ganglion Stimulator for Medical Necessity

A medical-necessity denial for a dorsal root ganglion (DRG) stimulator means BCBS's reviewer determined that the submitted documentation did not establish that the device is clinically required for this specific patient under BCBS's coverage criteria. This is the most common denial type for implantable neuromodulation devices and is also one of the most successfully overturned on appeal — because the denial is documentation-driven, not a categorical policy exclusion.

## Why This Is Appealable

Medical-necessity determinations by insurers are based on the documentation submitted. When a denial occurs, it often reflects a gap between what the chart contains and what BCBS's criteria require — not a genuine clinical disagreement. A well-organized appeal that maps the patient's specific clinical facts directly to each BCBS criterion typically results in reversal at internal or external review. The key is precision: vague statements of suffering do not satisfy criteria; documented objective measures do.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial. BCBS must respond within 30 days (pre-service standard), 72 hours (urgent/expedited), or 60 days (post-service). Request the full claim file and the specific criteria used to deny before preparing your appeal.
• External review (ACA §2719): File within 4 months of final internal denial. An independent IRO reviews without deference to BCBS. This is a strong avenue for medical-necessity disputes.
• ERISA §503 (self-funded plans): Full-and-fair review applies; federal courts may review whether BCBS applied its criteria consistently.
• Expedited review: Request if standard timelines pose a serious health risk.

## Documentation to Gather

1. Diagnosis confirmation — specialist evaluation, imaging, nerve conduction studies, or other objective testing confirming the pain diagnosis and its anatomical basis. 2. Functional severity assessment — validated pain scales, functional capacity assessments, or quality-of-life measures documenting the impact of the condition. 3. Complete prior treatment history — a dated, itemized list of all conservative treatments (medications, physical therapy, injections, procedures) tried before the DRG stimulator was recommended, with documented outcomes for each. 4. DRG trial results — if a stimulator trial was performed, objective pain and function outcome data from the trial period. 5. Implanting physician medical-necessity letter — a detailed clinical letter addressing each of BCBS's published coverage criteria for DRG stimulation, mapping specific patient facts to each requirement. 6. BCBS's current medical policy — obtain the live version from BCBS's medical policy library to ensure the appeal addresses each criterion verbatim.

## Criteria-Mapping Structure

| BCBS Medical Necessity Criterion | Specific Patient Documentation | |---|---| | Qualifying diagnosis confirmed | [Specialist report, imaging] | | Conservative treatment trial completed | [Dated treatment history] | | Functional impairment documented | [Validated assessment scores] | | Successful stimulator trial | [Trial outcome data] | | Appropriate patient selection confirmed by specialist | [Implanting physician letter] |